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In recent years, a large volume of medical and public health literature has
been dedicated to the sexually transmitted infection Human Papillomavirus
(HPV). The purpose of this paper is to provide a comprehensive assessment of
recent empirical investigations which assess the public health impact of HPV
and recent HPV vaccinations.
Epidemiologic Assessment
Human Papillomavirus is the most common sexually transmitted
infection in the United States (U.S.; Weinstock, Berman, & Cates, 2004). It
is estimated that 20 million people are currently infected with HPV and that
an additional 6 million new infections occur every year (Centers for Disease
Control and Prevention [CDC], 2009). Human Papillomavirus is a small DNA
virus that replicates in squamous epithelial cells found on the skin, cervix,
vagina, anus, vulva, head of the penis, mouth, and throat (Widdice & Kahn,
2006). It is passed from person-to-person via sexual intercourse or skin-to-skin
contact and can infect both men and women (Baseman & Koutsky, 2005). In
most cases, infections with HPV are not serious and are usually asymptomatic,
transient, and resolve without treatment (Baseman & Koutsky, 2005).
However, in some individuals HPV infections result in genital warts, cervical
abnormalities, and/or various cancers (CDC, 2009; Worden et al., 2008). Since
there are often no signs or symptoms of infection many individuals are unaware
of their possible transmission to others (CDC, 2009). It is estimated that 80%
of sexually active women will have acquired HPV by the age of 50 with a high
prevalence occurring from ages 14-19 (Datta et al., 2008; Myers, McCrory,
Nanda, Bastian, & Matchar, 2000). According to Manhart and colleagues (2006)
the prevalence of infection among women aged 18-25 increases from 14.3%
among those with one lifetime sexual partner to 31.5% with more than three
partners.
There are more than 100 different strains of HPV and many differ in
terms of the epithelium they infect. Some infect cutaneous sites whereas others
infect mucosal surfaces (Trottier & Franco, 2006). Over 40 strains are sexually
transmitted and can cause genital warts, cervical abnormalities, and/or cancer of
the oral cavity, oropharynx, anus, vulva, penis and vagina (CDC, 2009). The
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incidence of HPV-associated cancers/year is as follows: 12,000 cervical, 4,400
anal, 2,700 vulvar, 1,000 vaginal, and 1,000 penile (CDC, 2009). The strains
of HPV that cause cervical cancer differ from those that cause genital warts
(Munoz, Bosch, & deSanjose, 2003). Strains 16 and 18 are considered high risk
and have been detected in 99.7% of cervical cancer cases. Strains 6 and 11 are
considered low risk and account for 90% of genital wart cases. Most genital
infections will naturally clear without medical intervention (Munoz et al., 2003).
However, women who do not clear high risk strains are at an increased risk for
cervical cancer.
Human Papillomavirus causes cells on or around the cervix to become
abnormal and may progress to pre-cancerous stages (Collins, Mazloomzadeh, &
Winter, 2002). Many women may develop mild cytologic abnormalities causing
atypical squamous cells of undetermined significance (ASC-US) or low-grade
squamous intraepithelial lesions (LGSIL) as detected on a Papanicolau (Pap)
test (Munoz et al., 2003). In the U.S., approximately 4% to 5% of all cervical
cytology results are ASC-US (Munoz et al., 2003). These abnormal cells may
clear without treatment and most high-risk HPV infections do not result in
cancer (Munoz et al., 2003). Persistent infection is associated with adaptations
that can result in pre-cancer cells. True pre-cancer cell changes are called high
grade squamous intraepithelial lesions (SIL). Pap tests are used to identify
cervical cancer precursors that can be treated before progression to cervical
cancer occurs. The American Congress of Obstetricians and Gynecologists
(ACOG) recommends women start having Pap tests approximately three years
after the onset of vaginal intercourse but no later than age 21 (ACOG, 2003).
Selected strains of HPV can also cause genital warts. There is an
estimated 1 million new cases of genital warts each year in the U.S. (Kodner &
Nasraty, 2004). Genital warts are usually soft, flesh-colored growths that can
be raised or flat, small or large, alone or in clusters. They sometimes disappear
without treatment or may need to be removed by burning, freezing, laser or
surgical procedures. However, they can return after treatment because the viral
infection may be persistent. It is estimated that 25% of cases reoccur within
three months (Kodner & Nasraty, 2004).
The high prevalence rates of HPV-related strains have generated public
health interest in primary prevention methods focused upon risk reduction.
Transmission of HPV can be reduced through the correct and consistent use of
physical barriers such as male latex condoms (Winer et al., 2006). While HPV
can occur in areas that are not covered or protected by a condom, the use of
condoms has been associated with decreases in HPV-related problems. A study
conducted by Winer and colleagues (2006) assessed the relationship between
HPV infection and vaginal intercourse among 82 university students over an
eight month period. Results indicated that the participants who used condoms on
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all sexual occasions exhibited an incidence of genital HPV of 37.8/100 patientyears, whereas participants who used male condoms less than 5% of the time
had a rate of 89.3/100 patient-years.
According to the CDC (2010a):
Condom use may reduce the risk for HPV-associated diseases 			
(e.g., genital warts and cervical cancer) and may mitigate the other 		
adverse consequences of infection with HPV; condom use 			
has been associated with higher rates of regression 				
of cervical intraepithelial neoplasia (CIN) and clearance of 			
HPV infection in women, and with regression of 				
HPV-associated penile lesions in men.
In 2006, Merck Pharmaceuticals introduced a new vaccine titled
Gaurdasil® that helps to protect against HPV strains 6, 11, 16, and 18. The
prophylactic vaccine is made from non-infectious HPV L1 proteins and is
administered through a series of three intramuscular injections (.5-ml doses)
over a six month period (0, 2, and 6 months; CDC, 2007). Currently, the vaccine
is licensed for females and males ages 9 to 26 and costs $360 for the full series
(Food and Drug Administration [FDA], 2010; Harris, 2006). A second vaccine,
Cervarix®, was submitted to the FDA in 2008 and is currently available as a
bivalent vaccine that protects against HPV 16 and 18 (Lowy & Schiller, 2006).
The public health benefits of the vaccines would be expected to significantly
reduce HPV-related morbidity and mortality and reduce the overall economic
burden upon health care systems (De Melo-Martin, 2006). The vaccines
represent a major step toward the prevention of HPV and cervical cancer but
should not be used as a replacement for other prevention strategies such as
cervical cancer screenings or protective sexual behaviors.
The prevalence of HPV infection is high among college women and
young adults 20 to 24 years of age (Dunne, Unger, & Sternberg, 2007; Winer,
Lee, & Hughes, 2003). College women have a high risk of acquiring HPV when
compared to the general population because of their high-risk sexual behaviors
(Dunne et al., 2007; Winer et al., 2003). Dinger and Parsons (1999) studied
college students living in residence halls and in fraternity/sorority housing at
a northwestern university. Results indicated that 39.4% of students living in
fraternity/sorority housing reported having 6 or more sexual partners compared
to 22.8% of students living in residence halls. In addition, 15% of students
living in fraternity/sorority housing reported more than 20 acts of sexual
intercourse prior to the study compared to 5% of students living in residence
halls. According to the CDC (1997), only 29.6% of sexually active students
reported that they or their partner used condoms during their last act of sexual
intercourse.
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Barriers to Vaccination Acceptance
Recent studies have begun to focus upon the examination of potential
barriers to mandatory HPV vaccination as well as overall acceptance of the
vaccine by target populations. A solid understanding of potential barriers is
crucial for health care providers to enable them to effectively assist parents and
adolescents in their decisions regarding the vaccines (Zimet, 2009). Research
indicates that school-entry requirements of vaccinations have proven to be a
very efficacious method of protecting a large majority of school children from
vaccine-preventable diseases (Hinman, Orenstein, Williamson, & Darrington,
2002). Though the school-entry requirements for childhood vaccines vary from
state to state, every state offers parents the option to opt-out for medical reasons
and some allow exceptions based on religious or philosophical beliefs (Zimet,
2009). Studies also demonstrate that increased outbreaks of preventable diseases
occur when vaccination requirements are relaxed (Feikin et al., 2000; Omer et
al., 2006;Thompson et al., 2007). Controversy surrounding the quadrivalent
HPV vaccine received increased media attention when several states proposed
legislative efforts that would mandate HPV vaccination for girls entering middle
school (Zimet, 2009).
On February 2, 2007 Texas became the first state to mandate HPV
vaccination, requiring all girls to receive Gardasil® before entering 6th grade
(Cook, 2008). By March 2007, legislation had been introduced in 41 states and
the District of Columbia to “require, fund, or educate the public about the HPV
[v]accine” (Cook, 2008, p. 213-214). Of these, 24 states required vaccination
for enrollment in school, while the remaining 17 proposed policies that were
centered upon funding the vaccine or sponsoring education-based programs
(Cook, 2008).
Many parents view the efforts as an infringement upon their rights
and are weary of the safety and efficacy of the vaccine (Cook, 2008). Dissent
regarding school-entry vaccination requirements is centered upon the following
key arguments (a) currently, long-term safety and accessibility issues have not
been empirically assessed (b) fear that vaccination will promote increased sexual
activity among young girls and adolescents and (c) the vaccination will provide
a false sense of reduced susceptibility from other sexually transmitted infections
(Blumenthal, Heyman, Trocola, & Slomovitz, 2008).
Although few laws pertaining to school-entry requirements have been
enacted, research suggests that HPV vaccination utilization remains higher than
comparable non-mandated vaccines for preventable communicable diseases
(Jain, Stokley, & Yankey, 2008; Zimet, 2009).
In 2007, approximately 25% of 13-17 year old girls in the U.S. received
at least one dose of HPV vaccine and an estimated 68% of first dose
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recipients received at least two doses at the time of follow-up (Jain et al., 2008).
In contrast, a United Kingdom (U.K.) study of 2,817 girls attending 36 schools
found that nearly 71% received the first dose and 97% of first dose recipients
received the second (Brabin et al., 2008). Australian studies yield similar results
of high vaccine acceptance, with 3-dose uptake at 75 - 80% (Garland, 2008).
Another Australian study conducted by Fairley and colleagues (2009)
examined proportions of new clients presenting with genital warts beginning
in 2004 before vaccination programs were implemented in 2007 (Fairley et al.,
2009). In 2007, school-based and general practice programs began offering free
quadrivalent vaccination for school girls aged 12-18 years and women less than
26 years of age. In the period from 2004 – 2007, there was an increase in new
clients presenting with genital warts of 1.8% (95% CI 0.2% - 3.4%) per quarter
in women under 28 years of age. In comparison, there was a decrease of 25.1%
(95% CI 30.5% - 19.3%) in the proportion of women under 28 years presenting
with warts per quarter in 2008. The average quarterly change for heterosexual
men was a decrease of 5% (95% CI 0.5% -- 9.4%; p = .031). These findings
demonstrate that Australian and U.K. school-based vaccination approaches are
more effective than the U.S. clinic based-approach (Zimet, 2009).
Worldwide acceptance of the vaccines is increasing. As of September
2008, over 100 countries had licensed the quadrivalent vaccine and over 75
countries had licensed the bivalent vaccine (Irwin, 2008). Unfortunately, there
is a vast amount of misunderstanding and misperception regarding HPV and
cervical cancer. In general, young women, parents, and health care providers
appear to be interested in vaccines that prevent HPV, but there are varying
degrees of acceptance among the populations (Zimet, 2005). Recent studies of
physician attitudes regarding vaccination recommendations have revealed that
acceptance rates of physicians generally increased with the girl’s age (Mays &
Zimet, 2004; Raley, Followwill, Zimet, & Ault, 2004; Riedesel et al., 2005).
In 2005, Daley and colleagues (2006) conducted a national assessment of
vaccination-related attitudes among 294 U.S. pediatricians. Results indicated
that pediatricians believed that if a future vaccination was developed and
endorsed by a health-related organization, they would increasingly be willing
to recommend the vaccine to girls and boys based upon age. Vaccination
recommendation rates ranged from 46% (ages 10 to 12) to 89% (ages 16 to
18) in girls as well as 37% (ages 10 to 12) to 82% (ages 16 to 18) in boys. In
addition, only 11% of participants believed that the vaccine would encourage
sexual behavior among their patients (Daley et al., 2006). Other factors that
could influence acceptance beliefs include the potential economic and personal
benefits associated with decreased health care costs and stress due to abnormal
Pap results (Blumenthal et al., 2008; Harper, 2004).
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Studies reveal that sexually active college students ages 20 to 24
often lack knowledge regarding HPV and become more aware only after being
diagnosed with HPV infection by a health care provider (Vail-Smith & White,
1992; Yacobi, Tennant, Ferrante, Pal, & Roetzheim, 1999). Previous studies
have shown that 85% of college women have heard of HPV but are unaware of
the infectivity and overall prevalence of the virus (Vail-Smith & White, 1992;
Yacobi et al., 1999). A study by Lambert (2001) focused on college women’s
knowledge of HPV. The women were given a pre-questionnaire, participated in
a brief HPV-focused educational intervention, and were reevaluated 3 months
later. Results showed that the women answered 45% of the HPV questions
correctly pre-intervention and 78% correctly post-intervention. These findings
suggest that targeted intervention efforts may increase general knowledge in
specific populations potentially leading to adoption of preventative methods
such as receiving a vaccine.
Only 30% of women participants in two U.K. studies, as well as 13%
of adolescents in a Canadian study, had prior knowledge of HPV (Dell, Chen,
Ahmad, & Stewart, 2000; Pitts & Clark, 2002; Waller et al., 2003). Additional
research has shown that even among those who had prior knowledge of HPV,
many misunderstandings concerning infection, cervical cancer screening, and
Pap smears exist (Zimet, 2005). One investigation indicated that 86% of women
interested in learning about the virus believed that HPV-related educational
materials should be distributed to individuals before they initiate sexual activity
(Holcomb, Bailey, Crawford, & Ruffin, 2004). Another study of male and
female university students revealed that 74% of participants were willing to
receive the vaccine (Boehner, Howe, Bernstein, & Rosenthal, 2003). There were
no differences in acceptance rates based on gender or motivation for vaccination
(i.e., as an STI vaccine versus a reproductive health vaccine). Overall, this study
suggests that HPV vaccination is generally viewed as positive by young men
and women.
One important public health aspect of HPV for collegiate students
is the availability of the vaccinations within their health centers. A study
conducted in 2001 by Koumans and colleagues (2005) at the CDC assessed 910
colleges and universities nationally. Findings indicated that 60% of colleges and
universities host a student health center/health services. Butler 2009) assessed
the availability of the vaccine within 358 colleges and universities with student
health centers nationally. Results indicated that 72.3% currently offer at least
one form of the vaccine to their student population. Demographic characteristics
(size of college/university, geographic region, as well as non-faith-based
affiliation) were all significant factors in predicting vaccine availability. In
addition, health center institutional complexity and formalization were also
significant predictors.
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Age of Vaccination
The 2009 Youth Risk Behavior Survey reported that 65.0% of 12th
grade females had sexual intercourse; 52.5% of 11th grade; 39.6% of 10th grade;
and 29.3% of 9th grade (CDC, 2010b). The median prevalence of having ever
had sexual intercourse was 48.2% across state surveys (data ranged from 39.0%
to 61.0%). More surprisingly, 5.9% of students nationwide reported having had
sexual intercourse before the age of 13 and 8.8% of sexually active 9th graders
reported having had 4 or more lifetime sex partners. Based upon these statistics,
it is clear that HPV educational programs need to target younger populations
and their parents in order to increase vaccination in adolescents before initial
sexual activity which would greatly decrease their overall risk of cervical cancer
(Blumenthal et al., 2008).
Promotion of early vaccination is also important because data shows
that the efficacy and potential benefit of the vaccines is not as clear for women
older than 19 years as it is for adolescents under the age of 19 (Saslow et al.,
2007). However, females over the age of 19 who have not yet engaged in sexual
intercourse would still greatly benefit from the vaccine, and women aged 19 to
26 could still benefit if they have not been exposed to all HPV vaccine types.
The American Cancer Society (ACS) guidelines suggest that the three primary
factors to consider when recommending age to vaccinate are duration of
protection, age for optimal efficacy, and feasible plans for distribution (Saslow et
al., 2007). Since the vaccines are relatively new, duration studies are limited and
only include data from 3.5 to 5 years. The lower age limit for efficacy studies is
16 years of age for Gardasil® and 15 years of age for Cervarix®.
Differences between Specific Populations and Geographic Regions
Another barrier to global vaccination utilization rates is that vaccine
acceptance rates appear to differ among specific populations. One study revealed
that Latina immigrants unanimously agreed upon acceptance while African
Americans were more skeptical and cited concerns about effectiveness, side
effects, and potential for an increase in sexual activity (Scarinci, Garc´esPalacio, & Partridge, 2007). A study in Mexico examined the effect of HPV
education on vaccine acceptance (Lazcano-Ponce et al., 2001). After participants
were educated about the preventative factors of the vaccine regarding cervical
cancer, 84% of the women stated they would allow their teenage daughter to
be vaccinated. The effect of brief educational efforts is demonstrated in another
study which found that acceptance of the vaccine among parents of 10 to
15-year-old children rose from 55% to 75% after they read an information sheet
about HPV and vaccination; parents in opposition to the vaccine cited sexual
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disinhibition as a barrier (Davis, Dickman, Ferris, & Dias, 2004).
A separate review of studies of HPV beliefs in the United States found
that only 6 - 12% of parents were concerned that vaccination would lead to
increased sexual activity (Brewer & Fazekas, 2007). Furthermore, a study of
parental acceptance in California found that 75% of parents would be likely
to vaccinate a daughter before the age of 13 (Constantine & Jerman, 2007).
In comparing non-Hispanic parents to other populations, Hispanic parents
were more likely to accept vaccination, whereas African American and AsianAmerican parents were less likely. An investigation in England conducted by
Marlow, Waller, and Wardle (2007) revealed that 75% of mothers with children
in primary and secondary school settings were acceptant of vaccination. In
addition, mothers were found to be more acceptant of the vaccine if they were
categorized into the following traits (a) experienced cancer in their family, (b)
had older daughters, (c) had perceived approval from their spouse/significant
other, and (d) viewed vaccine acceptance as normative.
Health System Disparities
Other concerns are that current social and economic disparities
within the health care system have led to poor and minority populations being
disproportionately affected by cervical and other HPV-related cancers (Zimet,
2009). In 2003, researchers from the International Agency for Research on
Cancer conducted a meta-analysis of 57 studies which assessed the relationship
between social inequality and cervical cancer risk (Parikh, Brennan, & Boffetta,
2003). Results of the investigation revealed:
An increased risk of approximately 100 percent between high and low 		
social class categories for the development of invasive cervical cancer. 		
This increased risk was apparent in all geographic regions, although 		
it was stronger in Africa, Asia and Latin America and the Caribbean 		
than in Europe (Parikh, Brennan, & Boffetta, 2003, p. 687).
One of the most significant health disparities associated with cervical
cancer is the lack of screening. Cervical screening is a highly effective
prevention strategy that enables women to detect precancerous cervical
abnormalities early on (Erdman, 2009). According to Erdman (2009), “social
health disparities are unjust … because they result from government action that
adversely affects the health risks and outcomes of groups already disadvantaged
by virtue of their underlying social position” (p. 370 ). Governments all over
the world are failing to implement health measures for underserved populations,
thus creating health disparities and placing already disadvantaged populations
at increased risk (Erdman, 2009). General Comment No. 14 from the United
Nations Committee on Economic, Cultural, and Social Rights (CECSR)
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explicitly states:
Inappropriate health resource allocation can lead to discrimination 		
that may not be overt. For example, investments should 			
not disproportionately favour expensive curative health services which 		
are often accessible only to a small, privileged fraction of 			
the population, rather than primary and preventive 				
health care benefiting a far larger part of the population (2000).
Increasing the availability of cancer screening programs for disadvantaged
populations should be a high priority if the ultimate goal is to prevent worldwide
HPV prevalence.
Male Vaccination
Other policies and health measures that would facilitate an overall
HPV prevalence decrease are those directed specifically at males. If only
women are vaccinated, statistics indicate that 75% of HPV cases caused by the
four strains that the vaccine prevents would be prevented, whereas more than
90% of cases would be prevented if both males and females are vaccinated
(Cook, 2008). These statistics suggest that vaccinating males would be a very
effective preventative method in terms of decreasing HPV prevalence, but
some researchers are concerned with the cost-effectiveness of male vaccination
programs. Furthermore, until more research is conducted that links HPV to
cancer in men, acceptance and advocacy of male vaccination is unlikely.
Recent research conducted by Worden and colleagues (2008) shows a
possible link between HPV and cancer of the tongue and tonsils in men. In their
study, biopsies from 27 out of 42 (64.3%) oral cancer male and female patients
tested positive for HPV16. Positive HPV16 results were associated with younger
age (median, 55 v 63 years; p = .016), nonsmoking status (p = .037), and, most
importantly, sex (22 of 30 males [73.3%] versus 5 of 12 females [41.7%]; p
= .08). These results suggest that men with HPV infections have an increased
risk for oral cancer. The team suggests that vaccinating both male and female
adolescents should be considered because of the high risk of HPV associated
cancers in men. Current estimates from the ACS report that HPV DNA is present
in about one-third of oropharyngeal cancer cases and about one-half of tonsil
cancer cases (ACS, 2010). Considering that men accounted for more than twothirds (20,100) of the estimated 28,500 Americans who contracted oral cancer
in 2009, HPV vaccines for males could prove to be a very effective preventative
method (ACS, 2010).
Other researchers are focusing on the effectiveness of HPV vaccination
regarding the prevention of anal cancer in men (Lindsey, DeCristofaro, & James,
2009). The HPV quadrivalent vaccine Gardasil® may also prove to be effective
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for preventing anal cancer because the same four strains (types 6, 11, 16, and
18) that are the most common precursors to the development of cervical cancer
are also responsible for causing 80% of anal cancers (Lindsey et al., 2009).
Therefore, anal cancer could become a vaccine-preventable disease if the HPV
vaccine is effective for men (Lindsey et al., 2009). In a recent study of more than
4,000 males ages 16-26, sponsored by Merck & Co., Gardasil® was found to be
90.4% efficacious against HPV 6, 11, 16, and 18-related external genital lesions
(EGL; Merck & Co, Inc., 2009). Proponents of male vaccination argue that it
will also provide herd immunity which will ultimately significantly reduce the
risk of cervical cancer in unvaccinated women (Nath & Thappa, 2009). Future
research is needed to assess the causal role of HPV in various cancers as well as
the potential beneficial outcomes associated with large-scale vaccination efforts
in both male and female populations.
Efficacy
Efficacy analyses of the quadrivalent vaccine found that it was 98.2%
(CI = 93.5% - 99.8%) effective in protecting against HPV 16- or 18-related CIN
2/3 or AIS and 96.0% (CI = 92.3% - 98.2%) effective in protecting against any
CIN attributed to HPV 6, 11, 16 or 18 (FDA, 2010). Vaccine efficacy against
HPV 6- and 11-related external genital warts was 99.0% (CI = 96.2% - 99.9%)
and 100% (CI = 55.5 - 100.0) against HPV 16- or 18-related VIN 2/3.
The bivalent vaccine Cervarix® has also been proven to be highly effective
(Harper et al., 2006). After investigators conducted a combined analysis, the
results revealed that vaccine efficacy was 100% (95% CI, 42.4% -100%) in
preventing HPV16 or HPV18-related CIN in a study of women aged 15 to
25 years who received the recommended 3-dose vaccination regimen and
participated in a 4.5 year (44 to 53 months) follow-up. In addition, other
studies have found the bivalent HPV types 16, 18 vaccine to be more than
90% efficacious against incident infection, 100% efficacious against persistent
infection and 90.4% to 100% efficacious against HPV types 16, 18-related CIN
(Harper et al., 2004; Harper et al., 2006; Paavonen et al., 2007). Furthermore,
research shows the vaccine has more than 98% seropositivity after 4.5 years and
that cross-protection exists with the bivalent HPV types 16, 18 vaccine against
incident infection with HPV types 45 and 31 (Harper et al., 2006).
Adverse Effects
The future of HPV vaccination programs lies within current and
developing research studies. While research supporting the effectiveness of the
vaccines is the primary focus, reports on adverse effects of the vaccines
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will also play an important role in whether overall acceptance from the general
population, as well as from healthcare providers, increases or decreases.
In studies assessing the Cervarix® vaccine, vaccine recipients reported more
overall adverse events (injection site and systemic) when compared to placebo
recipients (92% versus 88% respectively; Villa et al., 2005). Investigators
of school-based vaccination programs in New South Wales have recently
estimated the rate of post-Gardasil® vaccine anaphylaxis to be 2.6/ 100,000
doses administered (95% CI 1.0 - 5.3 per 100,000; Brotherton et al., 2008). In
comparison, one case of anaphylaxis was identified in a 2003 meningococcal
C vaccination program (anaphylaxis rate of 0.1/100,000 doses administered;
95% CI 0.003 -- 0.7). Overall research results revealed that the estimated rate of
anaphylaxis following HPV vaccination was significantly higher than the rate
following comparable school-based vaccination programs.
Other research suggests that the immuno-stimulatory properties of
the Gardasil® vaccine may influence the occurrence and severity of CNS
demyelination in patients with known multiple sclerosis, however no direct
conclusions have been made regarding recommendations for the immunization
of these persons (Sutton, Lahoria, Tan, Clouston, & Barnett, 2009). Two postvaccination cases of status epilepticus with myoclonus (repeated and prolonged
seizures and loss of consciousness) in Spain have recently been reviewed by
the Committee for Medicinal Products for Human Use (CHMP) and have been
determined to be unlikely associated with the Gardasil® vaccine (European
Medicines Agency [EMEA], 2009). The EMEA has also issued a report
concerning the unexpected deaths of two females in the European Union (EU),
stating that both occurred post-Gardasil® vaccination, but the causes of death
could not be identified (EMEA, 2008).
As of December 31, 2008, more than 23 million quadrivalent HPV
doses had been distributed in the U.S. (Slade et al., 2009). Postlicensure data
from the U.S. Vaccine Adverse Event Reporting System (VAERS) for the 2.5
years following Gardasil® licensure has recently been released and analyzed.
At the time of release, VAERS had received 12,424 reports of adverse events
following immunization (AEFI) yielding a report rate of 53.9/100,000 doses.
Reports were submitted by the following: manufacturer (68%), providers (17%),
“others” (11%), patients or parents (4%), and state health clinics (1%). Due to
insufficient information, 7,561 (89%) of the manufacturer reports could not be
further reviewed. Gardasil® was the only vaccine identified in 80% of reports
(9,910 of 12,424). Females accounted for 97% (12,039 of 12,424) of reports,
and of the 47 reports on male vaccine recipients, 53% (25 of 47) were classified
as unintentional and 36% (17 of 47) as off-label use. The majority (61%) of the
9,396 reports (77%) listing dose information occurred after the first dose with
25% reported after the second dose, 13% after the third dose, and 1% reported
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after inadvertently receiving 4 or more doses. There was an average of 3.7
codes per report (range, 2--10; 46,932 codes for 12,424 reports) with the most
frequently reported AEFIs including syncope (n = 1,847, 15%), dizziness (n =
1,763, 14%), nausea (n = 1,170, 9%), headache (n = 957, 8%), and injection site
reactions (n = 926, 7.5%).
Of the 32 total reports of death, 20 (62.5%) had information available
to permit further evaluation. Seventy percent of cases (14 reports) were after
quadrivalent HPV alone, and the mean age was 18 years (median, 17 years;
range, 12-26 years); no clustering of age was determined. Causes of death were
generally classified as the following: unexplained (4), diabetic ketoacidosis
(2), prescription drug abuse (1), juvenile amyotropic lateral sclerosis (1),
meningoencephalitis (1), influenza B viral sepsis (1), pulmonary embolism (3),
cardiac-related deaths (6), and idiopathic seizure disorder (2).
Although data suggests no major complications during pregnancy, the vaccines
are not currently approved for pregnant women (Dawar, Dobson & Deeks,
2007). Data from 1,901 women who became pregnant during the Gardasil®
trials indicates similar results of pregnancy related adverse effects among
vaccine and placebo recipients (4.2% and 4.3%, respectively; Merck Frost
Canada, Ltd., 2006). Persons concerned with the safety of the vaccine can be
reassured by the CDC who continues to monitor vaccine-related side effects
and currently maintains that the vaccination is safe and effective for the
recommended populations (CDC, 2010c).
Future Directions
With the help of recent funding from the Bill & Melinda Gates
Foundation along with the National Institutes of Health (NIH), Richard
Schlegel, a primary researcher behind the development of Cervarix®, and his
team now have $3.5 million to use towards the creation of a new vaccine that
will be both preventative and therapeutic (Bloom, 2005). The team also plans to
combat transportation issues with the current vaccine formula (which must be
kept frozen) by developing a powder formula which can be easily transported to
developing countries and reconstituted with water. Researchers estimate that the
development of a more inclusive prophylactic vaccine could potentially lead to
a 70% or more reduction of cervical cancer risk (Saslow et al., 2007). According
to Saslow and colleagues (2007):
Ultimately, cervical cancer rates will depend on (1) the degree of 		
vaccination coverage of the at-risk population; (2) the number of 		
carcinogenic HPV types targeted by the prophylactic vaccine; (3) the 		
durability of protection; and (4) whether the medical community and 		
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the public continue to follow recommended screening guidelines (p. 		
18).
The possibility of continued protection from a HPV vaccine booster shot is
being researched, but the reduction of HPV incidence will depend upon the
percent of the population receiving the booster shot as well as the efficacy of the
booster (Saslow et al., 2007).
An assessment of the cost-effectiveness of Gardasil® by Kulasingam
and colleagues (2008) estimated that the vaccination of 100,000 girls would
result in a reduction of 400 cases of cervical cancer, 6,700 cases of cervical
intraepithelial neoplasia, and 4,750 cases of genital warts, suggesting that the
addition of HPV vaccine programs to current screening measures could prove
to be a cost-effective way to aid in the reduction of cervical cancer rates. In
addition, investigators at Stanford University estimated that if the Gardasil®
vaccine were implemented nationally in the U.S. to all 12 year old girls, 1,340
cancer-related deaths could be prevented over the target population’s lifetime
(Sanders & Taira, 2003). Researchers assessed factors such as lowered estimates
of vaccine efficacy (40%) and potentially required reoccurring booster shots
and concluded that the vaccine would be cost-effective even under these
circumstances.
According to Insinga, Glass, and Rush (2004), annual costs in 1998 for
cervical HPV-related disease in the U.S. are estimated to total about $3.4 billion
including the following expenditures (a) $2.1 billion for routine screening (b)
$300 million for false positives (c) $600 million for treatment of cervical precancerous conditions and (d) and $350 million for treatment of invasive cancer.
Estimates indicated that this value had grown to $5 billion by 2005 (Insinga,
2006). In addition, HPV-related health care costs were greater for HPV than
other sexually transmitted infections including Hepatitis B, genital herpes, and
Chlamydia (Insinga et al., 2004). A recent assessment by the ACS indicated that
about 30 women/day were diagnosed with cervical cancer in the United States in
2008 and the cost of cervical cancer screening and treatment is estimated to be
as high as $6 billion/year in the U.S. (Saslow et al., 2007).
Conclusion
A systematic review of the available literature reveals that HPV and
the accompanying vaccinations have significant public health implications in
the U.S. and abroad. Additional research is needed to assess the epidemiological
impact of large-scale vaccine implementation including the prevention of
HPV-related illnesses as well as the potential negative effects associated with
vaccination. As findings of ongoing empirical assessments become available,
30
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additional HPV-related health policies will be needed to ensure that the best
evidence-based public health practices are enacted.
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